WO2000029583A3 - Immunoglobulin superfamily proteins - Google Patents

Immunoglobulin superfamily proteins Download PDF

Info

Publication number
WO2000029583A3
WO2000029583A3 PCT/US1999/027566 US9927566W WO0029583A3 WO 2000029583 A3 WO2000029583 A3 WO 2000029583A3 US 9927566 W US9927566 W US 9927566W WO 0029583 A3 WO0029583 A3 WO 0029583A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin superfamily
igfam
superfamily proteins
provides
expression
Prior art date
Application number
PCT/US1999/027566
Other languages
French (fr)
Other versions
WO2000029583A2 (en
Inventor
Henry Yue
Y Tom Tang
Neil C Corley
Karl J Guegler
Gina A Gorgone
Mariah R Baughn
Dyung Aina M Lu
Preeti Lal
Jennifer L Hillman
Junming Yang
Original Assignee
Incyte Pharma Inc
Henry Yue
Y Tom Tang
Neil C Corley
Karl J Guegler
Gina A Gorgone
Mariah R Baughn
Dyung Aina M Lu
Preeti Lal
Jennifer L Hillman
Junming Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharma Inc, Henry Yue, Y Tom Tang, Neil C Corley, Karl J Guegler, Gina A Gorgone, Mariah R Baughn, Dyung Aina M Lu, Preeti Lal, Jennifer L Hillman, Junming Yang filed Critical Incyte Pharma Inc
Priority to AU16310/00A priority Critical patent/AU1631000A/en
Priority to CA002351313A priority patent/CA2351313A1/en
Priority to EP99959059A priority patent/EP1131428A2/en
Priority to JP2000582566A priority patent/JP2002530080A/en
Publication of WO2000029583A2 publication Critical patent/WO2000029583A2/en
Publication of WO2000029583A3 publication Critical patent/WO2000029583A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides human immunoglobulin superfamily proteins (IGFAM) and polynucleotides which identify and encode IGFAM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of IGFAM.
PCT/US1999/027566 1998-11-19 1999-11-19 Immunoglobulin superfamily proteins WO2000029583A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU16310/00A AU1631000A (en) 1998-11-19 1999-11-19 Immunoglobulin superfamily proteins
CA002351313A CA2351313A1 (en) 1998-12-22 1999-11-19 Immunoglobulin superfamily proteins
EP99959059A EP1131428A2 (en) 1998-11-19 1999-11-19 Immunoglobulin superfamily proteins
JP2000582566A JP2002530080A (en) 1998-11-19 1999-11-19 Immunoglobulin / Superfamily / Protein

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19585398A 1998-11-19 1998-11-19
US11363598P 1998-12-22 1998-12-22
US12819499P 1999-04-07 1999-04-07
US60/113,635 1999-04-07
US60/128,194 1999-04-07

Publications (2)

Publication Number Publication Date
WO2000029583A2 WO2000029583A2 (en) 2000-05-25
WO2000029583A3 true WO2000029583A3 (en) 2000-09-08

Family

ID=27381363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027566 WO2000029583A2 (en) 1998-11-19 1999-11-19 Immunoglobulin superfamily proteins

Country Status (4)

Country Link
EP (1) EP1131428A2 (en)
JP (1) JP2002530080A (en)
AU (1) AU1631000A (en)
WO (1) WO2000029583A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US20040141972A1 (en) 1997-11-21 2004-07-22 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU777006B2 (en) * 1998-12-16 2004-09-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7084500A (en) * 1999-09-03 2001-04-10 Human Genome Sciences, Inc. Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
WO2001068696A1 (en) * 2000-03-15 2001-09-20 Incyte Genomics, Inc. Human immune response proteins
EP1297137A2 (en) * 2000-06-23 2003-04-02 Biogen, Inc. Gp286 nucleic acids and polypeptides
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
CA2429195A1 (en) * 2000-11-16 2002-05-23 Incyte Genomics, Inc. Immunoglobulin superfamily proteins
EP1409655A4 (en) * 2001-03-12 2005-04-06 Incyte Genomics Inc Immunoglobulin superfamily proteins
WO2003008541A2 (en) * 2001-07-16 2003-01-30 Eli Lilly And Company Extracellular junctional adhesion molecules
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
US7405275B2 (en) 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
WO2006078766A2 (en) * 2005-01-19 2006-07-27 University Of Connecticut Methods and compositions for metastatic tumor screening
US20100168382A1 (en) * 2007-06-12 2010-07-01 Vladimir Berezin Neuroplastin derived peptides
DK2280996T3 (en) 2008-05-06 2016-12-19 Genentech Inc Affinity matured CRIg VARIANTS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737747A2 (en) * 1995-04-11 1996-10-16 Behringwerke Ag Cytoplasmatic expression in E. coli of antibodies, antibody fragments and fusions thereof
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO1997023613A2 (en) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Cell activation process and reagents therefor
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO1998002462A1 (en) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
WO1998011241A1 (en) * 1996-09-16 1998-03-19 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737747A2 (en) * 1995-04-11 1996-10-16 Behringwerke Ag Cytoplasmatic expression in E. coli of antibodies, antibody fragments and fusions thereof
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
WO1997023613A2 (en) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Cell activation process and reagents therefor
WO1997042329A1 (en) * 1996-05-04 1997-11-13 Zeneca Limited Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1997049809A1 (en) * 1996-06-24 1997-12-31 Rotkreuzstiftung Zentrallaboratorium Blutspendedienst Srk Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
WO1998002462A1 (en) * 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
WO1998011241A1 (en) * 1996-09-16 1998-03-19 Merck Patent Gmbh Oligocistronic expression system for the production of heteromeric proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLONNA M ET AL: "CLONING OF IMMUNOGLOBULIN-SUPERFAMILY MEMBERS ASSOCIATED WITH HLA-CAND HLA-B RECOGNITION BY HUMAN NATURAL KILLER CELLS", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 268, 21 April 1995 (1995-04-21), pages 405 - 408, XP002067321, ISSN: 0036-8075 *
DATABASE GENBANK 8 January 1998 (1998-01-08), PATERSON T.: ". sapiens mRNA for immunoglobulin kappa light chain", XP002132529 *
LI S ET AL: "A COMPUTER SCREENING APPROACH TO IMMUNOGLOBULIN SUPERFAMILY STRUCTURES AND INTERACTIONS: DISCOVERY OF SMALL NON-PEPTIDIC CD4 INHIBITORS AS NOVEL IMMUNOTHERAPEUTICS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 94, 1 January 1997 (1997-01-01), pages 73 - 78, XP000619663, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1131428A2 (en) 2001-09-12
WO2000029583A2 (en) 2000-05-25
JP2002530080A (en) 2002-09-17
AU1631000A (en) 2000-06-05

Similar Documents

Publication Publication Date Title
WO1999061471A3 (en) Human transmembrane proteins
WO2001012662A3 (en) Membrane associated proteins
WO2000015793A3 (en) Human gpcr proteins
WO2000000610A3 (en) Human signal peptide-containing proteins
WO2000022143A3 (en) Protein kinase homologs
WO2000029583A3 (en) Immunoglobulin superfamily proteins
WO2000018922A3 (en) Human carbohydrate-associated proteins
WO2000021988A3 (en) Human ankyrin family protein
WO2000034477A3 (en) Neuron-associated proteins
WO1999058692A3 (en) Human apoptosis associated proteins
WO2000012711A3 (en) Human membrane channel proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2001007612A3 (en) Receptors and associated proteins
WO2001005970A3 (en) Gtp-binding protein associated factors
WO2000014251A3 (en) Human transferase proteins
WO2000052151A3 (en) Human secretory proteins
WO2002072794A3 (en) Immunoglobulin superfamily proteins
WO1999058558A3 (en) Cell signaling proteins
WO2000028032A3 (en) Human cell surface receptor proteins
WO2000000594A3 (en) Human transferases
WO1999061614A3 (en) Human socs proteins
WO2000031263A3 (en) Gtpase associated proteins
WO2000028045A3 (en) Human hydrolase proteins

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16310

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09831805

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2351313

Country of ref document: CA

Ref country code: CA

Ref document number: 2351313

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 582566

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999959059

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999959059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999959059

Country of ref document: EP